Supriya Lifescience (SUPRIYA.NS) Hisse Fiyat

Supriya Lifescience Ltd. generates revenue through the manufacturing and export of active pharmaceutical ingredients (APIs) focused on niche therapeutic segments. The company produces approximately 38 API products, including Chlorphenamine Maleate, Pheniramine Maleate, and Cetirizine DiHCL, which address antihistamine, analgesic, vitamin, anesthetics, and anti-asthma therapies. These products are exported to around 86 countries, targeting pharmaceutical manufacturers and healthcare providers seeking specialized chemical compounds for drug formulations. The firm's manufacturing facilities in Maharashtra support the production of bulk drugs and pharmaceutical chemicals, with a strong emphasis on research and development to maintain its niche market position. The company's product portfolio includes specialized compounds such as Bisoprolol Fumarate, Nicorandil, and Mecobalamin, which cater to specific medical needs in cardiovascular and neurological treatments. By concentrating on high-demand therapeutic areas like antihistamines and anti-asthma solutions, Supriya Lifescience Ltd. serves pharmaceutical companies globally that require reliable sources of API raw materials. Its export-driven model ensures steady demand from international clients across diverse healthcare markets. Supriya Lifescience Ltd. leverages its research and development capabilities to develop and refine its API offerings, ensuring compliance with global pharmaceutical standards. The firm's focus on niche products allows it to differentiate itself in a competitive market, attracting buyers who prioritize specialized chemical solutions over generic alternatives. With a manufacturing base in Maharashtra, the company efficiently scales production to meet the growing global demand for its targeted therapeutic APIs.